- Home
- PMVP vs IMUX Comparison
PMVP vs IMUX Comparison
Compare PMVP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- IMUX
- Stock Information
- Founded
- PMVP 2013
- IMUX 2016
- Country
- PMVP United States
- IMUX United States
- Employees
- PMVP N/A
- IMUX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- IMUX Health Care
- Exchange
- PMVP Nasdaq
- IMUX Nasdaq
- Market Cap
- PMVP 77.4M
- IMUX 90.4M
- IPO Year
- PMVP 2020
- IMUX N/A
- Fundamental
- Price
- PMVP $1.14
- IMUX $0.77
- Analyst Decision
- PMVP Strong Buy
- IMUX Strong Buy
- Analyst Count
- PMVP 1
- IMUX 5
- Target Price
- PMVP $5.00
- IMUX $7.50
- AVG Volume (30 Days)
- PMVP 2.6M
- IMUX 1.4M
- Earning Date
- PMVP 11-06-2025
- IMUX 11-06-2025
- Dividend Yield
- PMVP N/A
- IMUX N/A
- EPS Growth
- PMVP N/A
- IMUX N/A
- EPS
- PMVP N/A
- IMUX N/A
- Revenue
- PMVP N/A
- IMUX N/A
- Revenue This Year
- PMVP N/A
- IMUX N/A
- Revenue Next Year
- PMVP N/A
- IMUX N/A
- P/E Ratio
- PMVP N/A
- IMUX N/A
- Revenue Growth
- PMVP N/A
- IMUX N/A
- 52 Week Low
- PMVP $0.81
- IMUX $0.56
- 52 Week High
- PMVP $1.84
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- PMVP 36.32
- IMUX 40.02
- Support Level
- PMVP $1.19
- IMUX $0.74
- Resistance Level
- PMVP $1.40
- IMUX $0.90
- Average True Range (ATR)
- PMVP 0.16
- IMUX 0.06
- MACD
- PMVP -0.04
- IMUX -0.00
- Stochastic Oscillator
- PMVP 1.41
- IMUX 21.24
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.